fluquadri
pharmacy retailing (nz) ltd t/a healthcare logistics - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) - suspension for injection - 60 mcg - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) excipient: octoxinol 9 phosphate buffered saline - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri is indicated for use in adults and children 6 months and older.
influvac inactivated influenza 0.5 ml vaccine long syringe needle free
mylan health pty ltd - influenza virus haemagglutinin -
influvac inactivated influenza 0.5 ml vaccine long syringe with 25 mm needle
mylan health pty ltd - influenza virus haemagglutinin -
influvac inactivated influenza 0.5 ml vaccine needle free syringe 2014
mylan health pty ltd - influenza virus haemagglutinin -
influvac sub-unit, suspension for injection (influenza vaccine, surface antigen, inactivated)
mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/cambodia/e0826360/2020 (h3n2)-like strain (a/cambodia/e0826360/2020, ivr-224); b/washington/02/2019-like strain (b/washington/02/2019, wild type) - suspension for injection in pre-filled syringe - 0.5 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen
influvac tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated)
mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen
influvac tetra
abbott medical laboratories ltd, israel - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - prophylaxis of influenza, especially those who run an increased risk of associated complications. influvac tetra is indicated in adults and children from 6 months of age.
influvac 45 mcg
مستودع أدوية أبوشيخة - abu sheikha drug store - influenza vaccine surface antigen 45 mcg - 45 mcg
influvac tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated)
viatris healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - influenza vaccines; influenza, inactivated, split virus or surface antigen
hexaxim
pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.